UCLA Vine Street Clinic
The UCLA Vine Street Clinic (UVSC) was established in 2005 in order to study the diffusion of HIV among methamphetamine user networks. Since that time, it has served as a site for clinical trials, behavioral research, and direct services focusing on the treatment of addiction, HIV prevention, and the intersection of the two. It is unique in its location, bringing the best in academia from UCLA into a transitional neighborhood of predominately working poor, an area designated as a medically underserved. The facility includes exam and counseling rooms for patient care and a lab for collection and storage of biological samples. Current projects on-going at the clinic are detailed below.
For more information and directions, or to schedule an appointment, call us at (323) 461-3106 or email us at [email protected].
Our Current Programs Include:
HPTN 103/Purpose 4: A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics and Safety of Twice Yearly Long-Acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in People Who Inject Drugs
Relevance: People who inject drugs remain at high risk for HIV due to a range of structural and social barriers, including stigma, limited healthcare access, and challenges with daily medication adherence. Traditional PrEP options may not meet the needs of this population, underscoring the importance of exploring new approaches to HIV prevention that are more accessible, discreet, and flexible.
Description: HPTN 103/Purpose 4 is a research study testing Lenacapavir, an injectable PrEP option given twice a year, to see if it can help prevent HIV in people who inject drugs. The goal is to understand whether this long-acting approach can reduce HIV risk by removing some of the daily barriers associated with oral PrEP. This study is part of the larger Purpose PrEP program and is being conducted at the UCLA Vine Street Clinic.
Status: This study is fully enrolled.
HPTN 113 “Double Prevention: A Vanguard Study of an Integrated Strategy of HIV PrEP and STI PEP for Young Latino Sexual Minority Men (SMM) in the Americas
RELEVANCE: People who benefit from HIV and STI prevention options, such as PrEP (pre-exposure prophylaxis), now have a choice of several biomedical prevention tools. However, PrEP uptake remains is lowest in groups experiencing a disproportionate impact of HIV, including Latino/e/x MSM and youth. More tools are needed to improve uptake and adherence of PrEP in this population.
DESCRIPTION: This is a multi-site, two part study. Part one (HPTN 113-01), includes focus groups where participants will engage in discussions to review mobile health tools and handouts (known collectively as the 3P mHealth package) that will be utlizied in the main study. Part two, (HPTN 113), is an individual-level randomized, open-label trial with participants assigned to receive either the 3P mHealth package or a PrEP education control. Participants will also be provided their choice of HIV PrEP agents/regimens and doxy-PEP for bacterial STI prevention.
STATUS: This study is currently on hold.
NIDA 1036 Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
RELEVANCE: There are currently no medications available for treating methamphetamine use disorder, highlighting a major gap in addiction medicine. This study aims to confirm the efficacy of naltrexone plus bupropion as a combination medication therapy to treat individuals with methamphetamine use disorder (MUD). This combination was shown effective in previous trials, including the much lauded ADAPT-2 study, the results of which were published in the New England Journal of Medicine in 2021. Successful results could bring us closer to an approval of a medication for this serious condition
DESCRIPTION: The primary objective of this double-blind, placebo-controlled, randomized clinical trial is to evaluate the efficacy of extended release naltrexone plus bupropion compared to matched injectable and oral placebo in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use. Individuals with moderate or severe MUD will be randomly assigned at a 1:1 ratio to receive either 1) extended-release naltrexone plus once daily oral extended-release bupropion tablets or 2) both the matching injection placebo and once daily oral placebo tablets. Participants will have visits twice weekly during the 12 week treatment phase and complete post treatment follow-up visits in weeks 14 and 16.
STATUS: We are currently enrolling. Please call us at 323-461-3106 for additional information or visit our sign up page.
FREE CONDOMS
According to a 1992 study published in the Journal of Sexually Transmitted Diseases, using a condom makes sex 10,000 times safer than not using a condom. The UCLA Vine Street Clinic has partnered with LA County to provide free condoms to the public. For more information, visit L.A. Condom.
Purpose 365: A Phase 3, Study of Once-Yearly Lenacapavir for PrEP
Relevance: The persistent barriers and suboptimal uptake of PrEP globally highlight the need for additional PrEP options. Lenacapavir (Len) has a long half-life and the potential to provide an additional option for people who want or need PrEP. It can help to address existing PrEP barriers beyond LEN administered every 6 months by further decreasing the frequency of injection.
Description: Purpose 365 is a single-arm, multisite research study to further assess the safety, tolerability, and pharmacokinetics of once-a-year injectable LEN in people with an indication for PrEP. This study is part of the larger Purpose PrEP program and is being conducted at the UCLA Vine Street Clinic.
Status: If you are interested in participating, please contact the UCLA Vine Street Clinic at 323-461-3106.
Development of the Stimulant Use Disorder Severity Scale (StUDSS)
RELEVANCE: Standard assessments used for diagnosis and severity of substance use disorder is through clinician-administered,structured interviews which can be costly, require extensive training, and involve lengthy administration times, making them impractical for repeated assessment in clinical trials.
DESCRIPTION: The purpose of this study is to advance the development of the Stimulant Use Disorder Severity Scale (StUDSS) as an FDA-qualified drug development tool.
STATUS: This study is currently on hold, but you can contact (323) 461-3106 for more information and to potentially be added to a waiting list.